SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to community discussion around earnings and a subsequent price dip, with debates focusing on valuation and the influence of Michael Burry's short position. Some are optimistic about a rebound, citing AI hype and strong fundamentals, while others express concern about overvaluation and potential downside. CEO Alex Karp's remarks about shorts on CNBC are also fueling discussion.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent earnings and trial data sparking debate, with discussion focused on the impact of a failed confirmatory trial on existing PMO therapies and the future of Elevidys. The community is weighing the potential for FDA action, the significance of 'missed' data, and whether the stock is now undervalued or facing further decline. Some traders see this as an opportunity for a short squeeze.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around its pursuit of Metsera and competition with Novo Nordisk in the obesity drug market, as well as an upcoming earnings report and dividend payout. The community is focused on the potential impact of the Metsera acquisition and whether Pfizer can maintain its competitive edge. Some traders are eyeing potential breakouts while others express frustration with the stock's historical performance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending after positive numbers sparked buyout speculation within the community, despite a generally negative market day. Community members are also closely following developments around patent extensions and potential new indications for AUR200. Some investors express frustration with management, while others remain optimistic about the company's long-term potential.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending as community members discuss a potential short squeeze amid high short interest and recent earnings. The company's turnaround efforts, including cost-cutting and diversification, are also key talking points. Bullish sentiment is building, especially with chatter around the Amazon partnership.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the meme-based crypto, emphasizing retail unity and a return to OG memecoin values. Community members express strong conviction and a belief in building a lasting movement, viewing $RAGE as more than just hype. The focus is on a cult-like community and the power of memes in the crypto space.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the price experiences volatility, sparking debates about whether this is a healthy pullback or the start of a deeper correction. Community discussions revolve around key support levels, potential bottom fishing opportunities, and whether institutions are driving the price action. Some traders express concern about overleveraged positions and the possibility of a crypto winter.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

UBER is trending as investors digest mixed signals post-earnings, balancing strong performance metrics with concerns about guidance and broader market conditions. Community discussions revolve around whether the dip represents a buying opportunity, with some highlighting the potential for long-term growth driven by autonomous vehicle initiatives. Several analysts have reiterated Buy ratings, noting robust growth, while others observe that the stock price has been disconnected from fundamentals.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as community members highlight its strong ties to the Bitcoin network and its fair distribution via airdrop. Discussion centers on $DOG being the premier meme coin on Bitcoin and the growing $DOG army. The connection between $DOG and $CBLO, a public company accumulating $DOG, is also a key talking point.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as it engages in a bidding war with Pfizer to acquire Metsera, a company with promising obesity drug assets; the community debates whether this acquisition strategy is the right move. Some believe Novo is strategically blocking a competitor, while others suggest focusing on share buybacks, particularly amidst concerns about market share competition with Eli Lilly. Recent messages also highlight anticipation for upcoming earnings and potential FDA approval for Novo's oral Wegovy.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Telomir Pharmaceuticals surged nearly 40% in premarket trading on Thursday after the company announced promising new lab results showing that its experimental compound, Telomir-1, can selectively destroy triple-negative breast cancer cells.In laboratory studies using human triple-negative breast cancer (TNBC) cells, researchers observed that as Telomir-1 concentrations increased, more cancer cells stopped growing and eventually died. When iron was reintroduced into the system, the cells regained their ability to survive, pointing to a finding that confirmed Telomir-1’s effects are tied to iron regulation and cellular energy balance.The discovery is significant as TNBC cells are highly dependent on iron to fuel their rapid growth and spread. By cutting off that iron-driven metabolism, Telomir-1 appears to exploit a key vulnerability in these tumors, while normal cells, which process iron differently, remain largely unaffected.Telomir-1 has previously&nbsp;demonstrated the ability to reset abnormal DNA methylation patterns, which are chemical modifications that can alter gene function in preclinical models of cancer and age-related diseases.&nbsp;In this latest study, researchers believe its impact on energy and iron metabolism may stem from its influence on certain enzymes, known as Jumonji domain histone demethylases, which are known to drive tumor aggressiveness and treatment resistance.The study suggests that Telomir-1 may help restore the body’s natural balance, reactivating the normal genetic controls that cancer cells&nbsp;typically shut down to maintain growth.Telomir said it will now seek to use the drug in other hard-to-treat cancers, such as pancreatic and blood cancers, based on these results. The company also expects to soon begin animal studies, a crucial step in the process of seeking FDA approval to begin human trials.On Stocktwits, retail sentiment for Telomir was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they were surprised the stock hadn’t “gone nuclear” after the breast cancer news broke, adding that they expect it to “go parabolic” in the next session.<stembedurl>https://stocktwits.com/DadiscplinedTrader/message/631612120</stembedurl>Another user commented that the company could eventually attract a buyout offer from a larger pharmaceutical player, suggesting the stock might rise ten to fifteen times, comparing it to past biotech acquisition successes, including that of Provention Bio by Sanofi.<stembedurl>https://stocktwits.com/MarketAttack/message/631581755</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir’s stock (TELO) has declined 60% so far in 2025. | Image source: Getty Images

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today

The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.

Equity

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Telomir Pharmaceuticals' anti-aging expert to present pre-clinical data

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase...

UPDATE   Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1  to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times...

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditionsBALTIMORE, March 14, 2024 (GLOBE NEWSWIRE...

Telomir Pharmaceuticals presents preclinical data for Telomir-1

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related...

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Telomir Pharmaceuticals Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.47
Prev Close	$1.50
Open	$1.50
Dividend Yield	0.00%
50-Day Moving Average	$1.46
Beta	0.94
Avg. Volume	4.02M
PE Ratio	-2.77

52-Week High	$7.08
52-Week Low	$1.12
Market Capitalization	$48.42M
EPS (Annual)	-$0.5597
Price to Book	95.12
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TELO News

TELOTelomir Pharmaceuticals Inc